04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
15:59 , Nov 16, 2018 |  BC Week In Review  |  Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
00:26 , Nov 16, 2018 |  BC Extra  |  Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on Thursday in a deal that highlights how far Arena’s come since it shifted its focus...
20:37 , Feb 23, 2018 |  BC Week In Review  |  Company News

Everest gets rights to Tetraphase antibiotic

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) granted C-Bridge-backed Everest Medicines Ltd. (Boston, Mass.) exclusive rights to develop and commercialize eravacycline (TP-434) in China, Taiwan, Hong Kong, Macau, South Korea and Singapore. Tetraphase will receive $7 million up...
23:46 , Feb 20, 2018 |  BC Extra  |  Company News

Everest gets rights to Tetraphase antibiotic

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) granted C-Bridge-backed Everest Medicines Ltd. (Boston, Mass.) exclusive rights to develop and commercialize eravacycline (TP-434) in China, Taiwan, Hong Kong, Macau, South Korea and Singapore. Tetraphase will receive $7 million up...
19:08 , Jan 19, 2018 |  BioCentury  |  Finance

Incubating in China

C-Bridge Capital is one of the newer venture funds in Chinese healthcare seeking to bring mature platforms or programs from the Western market into China. Compared with most other Chinese VCs, however, C-Bridge is investing...
02:55 , Dec 8, 2017 |  BC Week In Review  |  Company News

Arena grants newco Everest Chinese rights to candidates

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) granted Everest Medicines Ltd. (Boston, Mass.) exclusive rights to develop and commercialize ralinepag (APD811) and etrasimod (APD334) in China, Taiwan, Hong Kong, Macau and South Korea. Arena will receive $12 million...
20:06 , Dec 5, 2017 |  BC Extra  |  Company News

Newco Everest gains Chinese rights to Arena candidates

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) granted Everest Medicines Ltd. (Boston, Mass.) exclusive rights to develop and commercialize ralinepag (APD811) and etrasimod (APD334) in China, Taiwan, Hong Kong, Macau and South Korea. Arena will receive a $12...
20:22 , Nov 3, 2017 |  BioCentury  |  Regulation

Frame work

A little over four years into its implementation, FDA’s structured benefit-risk framework appears to be meeting its objectives of creating transparency into its approval decisions. The agency began to incorporate the framework templates into its...
23:46 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Arena's ralinepag meets primary in Phase II for PAH

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) reported top-line data from the Phase II APD811-003 trial in 61 patients with pulmonary arterial hypertension (PAH) showing that oral ralinepag (APD811) met the primary endpoint of improving the absolute change...